Since several solid tumors (e.g. ovarian cancer and melanoma) constitutively express or are induced to express MHC-II upon encountering IFN-γ and thus become direct targets of TR-CD4, the generation of effective TR-CD4 responses has significant therapeutic potential and broad clinical relevance27, 28. The gene discussed is CD4; the disease is ovarian carcinoma.